Sanofi (France) (SAN.PA) Aims to be Pharma's Top R&D Organization
6/1/2012 7:38:17 AM
Sanofi aims to build on its diabetes portfolio, which has so far relied on blockbuster insulin Lantus, with a wider range of treatments that could address not just the disease but also its numerous complications, its research head said on Thursday. Elias Zerhouni would not say, however, whether these goals include an interest in acquiring Amylin Pharmaceuticals, a U.S. specialist in diabetes therapies. "We used to be an insulin company, now we want to be a diabetes company," Zerhouni told reporters. "We want to offer an entire range of solutions."